https://scholars.lib.ntu.edu.tw/handle/123456789/495104
標題: | Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer | 作者: | CHIA-CHI LIN CHIH-HSIN YANG |
公開日期: | 2009 | 卷: | 4 | 期: | 1 | 起(迄)頁: | 37-44 | 來源出版物: | Targeted Oncology | 摘要: | Elderly and poor performance status advanced non-small cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the treatment of advanced NSCLC. Several phase II trials have been conducted utilizing EGFR TKIs in elderly or poor performance status patients with advanced NSCLC. This review will summarize the results of erlotinib or gefitinib in these subsets of patients with advanced NSCLC. ? 2009 Springer-Verlag. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-67349151088&doi=10.1007%2fs11523-009-0104-2&partnerID=40&md5=12d29d4b1b7bc63af1b7fe4b16fdbb82 https://scholars.lib.ntu.edu.tw/handle/123456789/495104 |
ISSN: | 1776-2596 | DOI: | 10.1007/s11523-009-0104-2 | SDG/關鍵字: | 4 [3 chloro 4 (2 pyridinylmethoxy)anilino] 3 cyano 6 (4 dimethylaminocrotonamido) 7 ethoxyquinoline; 6 [4 (4 ethyl 1 piperazinylmethyl)phenyl] 4 (alpha methylbenzylamino) 7h pyrrolo[2,3 d]pyrimidine; antineoplastic metal complex; BIBW 2992; canertinib; carboplatin; docetaxel; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; gemcitabine; navelbine; paclitaxel; pelitinib; pf 00299804; placebo; taxane derivative; unclassified drug; vandetanib; xl 647; alopecia; anemia; anorexia; bacterial pneumonia; cancer chemotherapy; cancer patient; chemotherapy induced emesis; chronic obstructive lung disease; clinical trial; deep vein thrombosis; diarrhea; drug fatality; fatigue; febrile neutropenia; hematuria; human; lung adenocarcinoma; lung alveolus cell carcinoma; lung non small cell cancer; monotherapy; multiple cycle treatment; neutropenia; overall survival; peripheral neuropathy; priority journal; prognosis; quality of life; rash; review; skin toxicity; unspecified side effect; Age Factors; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Humans; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Receptor, Epidermal Growth Factor; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。